| Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (NCT05219435) | Spanish Oncology Genito-Urinary Group | 2022-07-06 |
| A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy (NCT05366725) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-06-29 |
| Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (NCT05126433) | Jazz Pharmaceuticals | 2022-03-03 |
| Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors (NCT05279690) | Icahn School of Medicine at Mount Sinai | 2022-02-14 |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (NCT05059522) | Pfizer | 2021-09-29 |
| Sacituzumab Govitecan Plus EV in Metastatic UC (NCT04724018) | Dana-Farber Cancer Institute | 2021-05-20 |
| A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma (NCT04501094) | National Cancer Institute (NCI) | 2020-10-26 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136) | Dan Zandberg | 2020-09-14 |
| Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (NCT04294277) | European Association of Urology Research Foundation | 2020-07-13 |
| Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies (NCT04235777) | National Cancer Institute (NCI) | 2020-07-13 |
| Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery (NCT07413120) | Incheon St.Mary's Hospital | 2020-05-07 |
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (NCT04223856) | Astellas Pharma Global Development, Inc. | 2020-03-30 |
| Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer (NCT04131634) | University of Texas Southwestern Medical Center | 2020-01-16 |
| Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (NCT04180371) | BicycleTx Limited | 2019-11-07 |
| Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) (NCT03425201) | Fundacion CRIS de Investigación para Vencer el Cáncer | 2019-10-14 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (NCT04044859) | USWM CT, LLC | 2019-08-20 |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (NCT03474107) | Astellas Pharma Global Development, Inc. | 2018-06-27 |
| Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (NCT03406650) | Swiss Cancer Institute | 2018-05-15 |
| A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) (NCT03472560) | Pfizer | 2018-05-02 |
| GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors (NCT03576131) | Genmab | 2018-04-30 |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (NCT03390504) | Janssen Research & Development, LLC | 2018-03-23 |
| Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies (NCT03317496) | Pfizer | 2017-12-21 |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (NCT03288545) | Astellas Pharma Global Development, Inc. | 2017-10-11 |
| A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (NCT03219333) | Astellas Pharma Inc | 2017-10-08 |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NCT03207867) | Novartis Pharmaceuticals | 2017-08-28 |
| A Phase I Trial of LY3143921 Hydrate in Solid Tumours (NCT03096054) | Cancer Research UK | 2017-06-21 |
| Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (NCT03036098) | Bristol-Myers Squibb | 2017-03-24 |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients (NCT02661100) | Case Comprehensive Cancer Center | 2017-01-01 |
| Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder (NCT02891161) | Monika Joshi, MD | 2016-11-16 |
| RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy (NCT02880345) | Abramson Cancer Center at Penn Medicine | 2016-08-01 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (NCT02769962) | National Cancer Institute (NCI) | 2016-05-09 |
| A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) (NCT02603432) | Pfizer | 2016-04-25 |
| Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer (NCT02516241) | AstraZeneca | 2015-11-02 |
| An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer (NCT02365597) | Janssen Research & Development, LLC | 2015-04-22 |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) (NCT02393248) | Incyte Corporation | 2015-02-27 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052) (NCT02335424) | Merck Sharp & Dohme LLC | 2015-02-24 |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) (NCT02256436) | Merck Sharp & Dohme LLC | 2014-10-22 |
| A Study of TAS-120 in Patients With Advanced Solid Tumors (NCT02052778) | Taiho Oncology, Inc. | 2014-07-21 |
| Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen. (NCT02033993) | Canadian Cancer Trials Group | 2014-03-11 |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (NCT02111850) | National Cancer Institute (NCI) | 2014-02-07 |
| Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer (NCT01700010) | University of Michigan Rogel Cancer Center | 2012-11-01 |
| Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) (NCT01663285) | University of Michigan Rogel Cancer Center | 2012-09-01 |
| The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (NCT01801137) | Hopital Foch | 2011-06-01 |
| Phase II Study of TKI258 in Advanced Urothelial Carcinoma (NCT00790426) | Novartis Pharmaceuticals | 2010-03-01 |
| Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer (NCT00995488) | University of Michigan Rogel Cancer Center | 2009-10-01 |
| Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer (NCT01206426) | University of Chicago | 2009-10-01 |
| A Genotype-Phenotype Urothelial Cancer Registry (NCT00902590) | Memorial Sloan Kettering Cancer Center | 2009-05-01 |
| Gemzar, Cisp, Sunitinib Urothelial Ca (NCT00821327) | US Oncology Research | 2008-08-01 |
| SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial (NCT00578526) | AHS Cancer Control Alberta | 2008-04-01 |
| Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer (NCT00872495) | Lahey Clinic | 2002-09-01 |